Scribe Therapeutics Picks Cholesterol-Lowering As First In Vivo Gene Target
Scrip
|
February 7, 2024
X min read
Scrip
|
February 7, 2024
Share on Social
More like this
News
Scribe Therapeutics Presents Data on its Epigenetic Long-Term X-Repressor Technology at the 2025 Keystone Symposia on Precision Genome Engineering Conference
March 7, 2025
Read Now
Press
Scribe Therapeutics Presents Data on its Epigenetic Long-Term X-Repressor Technology at the 2025 Keystone Symposia on Precision Genome Engineering Conference
March 7, 2025
Read Now
